Comments on: The Threat To A Big Seller: Merck, Teva & Singulair http://www.pharmalot.com/2008/11/the-threat-to-a-big-seller-merck-teva-singulair/ News, Comment and Conversation Fri, 10 Feb 2012 20:58:15 +0000 http://wordpress.org/?v=2.6.2 By: katie http://www.pharmalot.com/2008/11/the-threat-to-a-big-seller-merck-teva-singulair/#comment-388646 katie Thu, 19 Feb 2009 20:16:53 +0000 http://www.pharmalot.com/?p=17355#comment-388646 Come talk to me about patent rights when you can't get your Singulair that you need for asthma because your doctor can't get pre-approval from your medical carrier and you can't afford it without your insurance cause it's $145 for 30 pills. Until then, shut up. Come talk to me about patent rights when you can’t get your Singulair that you need for asthma because your doctor can’t get pre-approval from your medical carrier and you can’t afford it without your insurance cause it’s $145 for 30 pills. Until then, shut up.

]]> By: Nathan http://www.pharmalot.com/2008/11/the-threat-to-a-big-seller-merck-teva-singulair/#comment-380613 Nathan Thu, 06 Nov 2008 17:32:40 +0000 http://www.pharmalot.com/?p=17355#comment-380613 This is getting ridicules. If the courts don't hold up our patents, then our industry is finished. I can understand challenges based on formulations, dosing, etc. But Teva is challenging the patents that form the very bedrock of the pharma industry: composition-of-matter patents. Teva is shooting themselves in the foot. They may get additional revenue in the short term, but they are pushing pharma more and more towards biologics -- which they cannot compete with for the foreseeable future. This is getting ridicules. If the courts don’t hold up our patents, then our industry is finished. I can understand challenges based on formulations, dosing, etc. But Teva is challenging the patents that form the very bedrock of the pharma industry: composition-of-matter patents.

Teva is shooting themselves in the foot. They may get additional revenue in the short term, but they are pushing pharma more and more towards biologics — which they cannot compete with for the foreseeable future.

]]>